Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00896012 · ClinicalTrials.gov registry record · Phase 4
Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal
A Phase 4 study, sponsored by University at Buffalo.
- Completed
- Registry status
- Phase 4
- Development phase
- 58
- Enrollment target
NCT00896012: Completed Phase 4 study, sponsored by University at Buffalo.
NCT00896012 is a Phase 4 study that has completed, run by University at Buffalo. The registered enrollment target is 58 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00896012, a Phase 4 study, has completed, sponsored by University at Buffalo.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 58 participants
- Enrollment target
Study Summary
Current therapy to prevent organ rejection relies on the use of calcineurin inhibitors either cyclosporine or tacrolimus. Although these agents have been very successful in preventing early acute rejection, this success has not translated into improved long-term kidney transplant function. One of the important factors that leads to premature kidney transplant failure is chronic allograft nephropathy (CAN). CAN is characterized by progressive interstitial fibrosis or "scarring", vascular wall thickening, and finally glomerular sclerosis leading to slow progressive loss of kidney function. Calcineurin inhibitors have been shown to play an important role in the pathogens of CAN. Renal transplant recipients in whom calcineurin inhibitors are discontinued enjoy better and longer kidney function. Therefore, immunosuppressive strategies are being designed with the intention of withdrawing calcineurin inhibitors. The purpose of this trial is to test if tacrolimus can be safely substituted by sirolimus (Rapamycin) and this substitution will yield improved renal function, less CAN and better graft survival rates over the first year.
Primary Outcome
Graft survival is defined as no rejection or inflammation at 12 months.
Interventions
- DRUG Tacrolimus
- PROCEDURE Kidney Biopsy
- DRUG Rapamune (sirolimus/rapamycin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2008-01 |
| Est. Completion | 2011-12 |
| Phase | Phase 4 |
What the finished NCT00896012 record still lists
NCT00896012 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 3 interventions - of which Tacrolimus is the first listed.
NCT00896012 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00896012 about?
NCT00896012 is a clinical study titled "Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal". Current therapy to prevent organ rejection relies on the use of calcineurin inhibitors either cyclosporine or tacrolimus. Although these agents have been very successful in preventing early acute rejection, this success has not translated into improved long-term kidney transplant function. One of th...
What is the current status of trial NCT00896012?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 58 participants. The study started on 2008-01. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00896012?
The interventions under investigation include: Tacrolimus (DRUG), Kidney Biopsy (PROCEDURE), Rapamune (sirolimus/rapamycin) (DRUG).
Who is sponsoring clinical trial NCT00896012?
This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00896012's enrollment target sits among peer trials
58 1205th of 2000 higher than 792 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia